CD274 and neoplasm: Checkpoint inhibitors (anti-CTLA4, anti-PD-1/anti-PD-L1, anti-LAG-3, anti-BTLA), as well as agonists of CD40 or TLR, are also known to improve anti-tumor T cell survival (45–49).